Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the overlap and differences between autism and MCDD as neuropsychiatric childhood disorders. MRI scans are acquired from subjects with autism, subjects with a diagnosis of MCDD and typically developing controls. Volumetric measure of various brain regions are compared between groups. We hypothesize that subjects with autism will have larger brains than controls, whereas subjects with MCDD will have smaller brains.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autism and Childhood-onset Schizophrenia have been clearly defined as neuropsychiatric disorders since the studies of Kolvin and Rutter. In the early seventies the discussion on a possible overlap between the two types of disorders vanished, but nowadays this issue revives. Amongst all the advances of the DSM diagnostic criteria, the omission of developmental information appears to be a disadvantage. The Pervasive Developmental Spectrum is a broad spectrum, that with exceptions for Autism and some other characteristic disorders, to a large extent consists of an ill-defined restcategory. Most patients actually belong to this last category , the so-called PDD-NOS group. In recent years more has been published about the subgroups within this large group. One of these subgroups, the Multiple Complex Developmental Disorder (MCDD), appears to be a well defined category of patients whose validity has been confirmed by research. In adulthood, a large percentage of this MCDD group seems to develop Schizophrenia or a Schizophrenia related disorder. This again does arise the question of a possible overlap. This discussion is even emphasized by reports notably on -mostly retrospective- studies of premorbid autistic features in patients with Schizophrenia.

In the present day studies on neurodevelopmental psychiatric disorders, there is a search for biological markers or discriminating factors. One of the applied methods is structural imaging. Question marks can be placed on the differing study set-ups and protocols which seriously hinder their inter alia comparison. However one can still conclude that the results of studies on subjects with Autism and Childhood-onset Schizophrenia reveal major differences. However, structural abnormalities do not tell anything about possible functional abnormalities. But detecting structural abnormalities can be helpful in forming hypothesis about the origin of these neurodevelopmental disorders.

In this study brain structures will be measured by magnetic resonance imaging. Structural deviances will be interpreted as a reflection of functional abnormalities. It is hypothesized that the abnormalities on structural imaging in MCDD patients will more resemble the abnormalities found in the literature for (Childhood-onset) Schizophrenia instead of the deviances revealed in subjects with Autism.

In this study patients with Autism and MCDD will be divided in two groups: before and after puberty. Each group will behold 15-40 subjects. They each will be compared with two groups of 20-25 age, sex and IQ matched controls. They will participate in carrying out a MRI scan, filling in some questionnaires and if necessary an IQ test and a general physical examination.The MRI scans will be measured, and compared with each other in order to find 'disorder-specific' abnormalities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Developmental Disabilities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of autism according to ADI-interview or diagnosis of MCDD according to the MCDD-checklist or no psychiatric diagnosis (controls)

Exclusion Criteria

* Some medical and neurological diseases (if there are influences on the brain structures)
* Alcohol or drug abuse
* IQ \< 70
* Focal abnormalities on the MRI scan

Minimum Eligible Age

7 Years

Maximum Eligible Age

24 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bertine E Lahuis, M.D.

Role: PRINCIPAL_INVESTIGATOR

Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht

Sarah Durston, Ph.D.

Role: STUDY_DIRECTOR

Rudolf Magnust Institute of Neuroscience, UMC Utrecht

Herman van Engeland, M.D. Ph.D.

Role: STUDY_CHAIR

Rudolf Magnus Institute of Neuroscience, UMC Utrecht

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Child and Adolescent Psychiatry, UMC Utrecht

Utrecht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Palmen SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Durston S, Lahuis BE, Kahn RS, Van Engeland H. Increased gray-matter volume in medication-naive high-functioning children with autism spectrum disorder. Psychol Med. 2005 Apr;35(4):561-70. doi: 10.1017/s0033291704003496.

Reference Type RESULT

PMID: 15856726 (View on PubMed)

Palmen SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Janssen J, Kahn RS, van Engeland H. Larger brains in medication naive high-functioning subjects with pervasive developmental disorder. J Autism Dev Disord. 2004 Dec;34(6):603-13. doi: 10.1007/s10803-004-5282-2.